Physical Activity and Type 2 Diabetes: When and How Much?

Both the timing and amount of physical activity are important in risk reduction and management of type 2 diabetes.

SUSTAIN-6: Cardiovascular Safety of Semaglutide in Type 2 Diabetes

Researchers found the cardiovascular safety of semaglutide was noninferior to placebo in high-risk patients with type 2 diabetes.

How Do We Use Technology for Diabetes Management?

Edward C. Chao, DO, highlights important considerations for developing technology for diabetes management.

Implementing Diabetes Self-Management Education in Type 2 Diabetes

Joan K. Bardsley, MBA, RN, CDE, describes a joint position statement regarding implementation of diabetes self-management education.

Role of the Gut Microbiome in Diabetes

Research shows that further understanding of the gut microbiome may improve diagnosis, prevention, and treatment of the disease earlier in life.

Preventing Diabetes and Complications: What Are the Challenges?

A change in how patients and physicians view diabetes may is necessary for preventing the disease and its complications.

LEADER: Liraglutide Decreased Rate of CV Events in High-Risk Type 2 Diabetes

Compared with placebo, liraglutide decreased the rate of cardiovascular events in high-risk patients with diabetes.

SGLT2 Inhibitors: A Class Effect?

Data on cardiovascular benefits as well as adverse effects have thrust this class of diabetes drugs into the spotlight.

Physical Activity Deficiency: A New Risk Factor for Type 2 Diabetes?

Sedentary behaviors may boost risk for type 2 diabetes by 22% and risk for metabolic syndrome by 39%.

AACE Issues Consensus Statement on Outpatient Glucose Monitoring in Diabetes

The new consensus statement reflects the advances made in glucose monitoring technology and offers guidance for clinicians.

AACE/ACE Updates Algorithm for Type 2 Diabetes Management

The American Association of Clinical Endocrinologists' updated algorithm for type 2 diabetes management addresses lifestyle modifications and obesity treatments.

Video

Latest Headlines

Anxiety Increased Mortality Risk in Type 2 Diabetes

Anxiety Increased Mortality Risk in Type 2 Diabetes

For individuals with type 2 diabetes, anxiety symptoms affect mortality risk, independently of depression symptoms, and attenuate the excess mortality associated with depression.

Cardiovascular Risk With Sitagliptin in Older Patients With Type 2 Diabetes

Cardiovascular Risk With Sitagliptin in Older Patients With Type 2 Diabetes

Sitagliptin has a neutral effect on cardiovascular risk among older patients with type 2 diabetes.

Type 2 Diabetes Associated With Some Apolipoproteins

Type 2 Diabetes Associated With Some Apolipoproteins

Apolipoprotein (apo) CIII and apoCIII-to-apoA1 ratio are correlated with incident type 2 diabetes.

Type 2 Diabetes Risk Tied to Omega-3 Fatty Acid Consumption

Type 2 Diabetes Risk Tied to Omega-3 Fatty Acid Consumption

Consumption of single omega-3 is associated with an increased risk of type 2 diabetes, with dosage, ethnicity, trial duration, and recruited age influencing the effect.

Adipose Tissue Insulin Resistance Increased in Obese Patients

Adipose Tissue Insulin Resistance Increased in Obese Patients

Resistance to the antilipolytic effect of insulin is increased in obese individuals with normal glucose tolerance, and in those with impaired glucose tolerance and type 2 diabetes.

Lactobacillus Supplement Did Not Affect HbA1c in Type 2 Diabetes

Lactobacillus Supplement Did Not Affect HbA1c in Type 2 Diabetes

Patients receiving the highest dose of L. reuteri have increases in insulin sensitivity index vs baseline.

SGLT2 Inhibitor Effective With Low-Carb, High-Carb Diet in Type 2 Diabetes

SGLT2 Inhibitor Effective With Low-Carb, High-Carb Diet in Type 2 Diabetes

For patients with type 2 diabetes, the SGLT2 inhibitor luseogliflozin has similar efficacy when meals contain 40% to 55% total energy from carbohydrate.

ACP Issues New Guideline for Oral Pharmacologic Treatment of Type 2 Diabetes

ACP Issues New Guideline for Oral Pharmacologic Treatment of Type 2 Diabetes

The ACP has updated the 2012 guideline to provide clinical recommendations of oral pharmacologic treatment of type 2 diabetes.

Postprandial Hyperglycemia Associated With CVD in Type 2 Diabetes

Postprandial Hyperglycemia Associated With CVD in Type 2 Diabetes

Postprandial hyperglycemia is linked to cardiovascular disease in patients with type 2 diabetes, regardless of HbA1c.

Life Years Lost Varies With Ethnicity in Patients With Type 2 Diabetes

Life Years Lost Varies With Ethnicity in Patients With Type 2 Diabetes

Whites with type 2 diabetes have more life years lost than South Asians or blacks.

Sign Up for Free e-Newsletters